Search
01/07/2022
Beyond plaque psoriasis - pathogenesis and treatment of other psoriasis phenotypes
Iznardo, H, Puig, L. Beyond plaque psoriasis - pathogenesis and treatment of other psoriasis phenotypes. CURRENT OPINION IN RHEUMATOLOGY. 2022; 34(4)DOI:10.1097/BOR.0000000000000882. PMID:35699337. IF:5.100(Q2/3D).
01/07/2022
Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis
Serra-Baldrich, E, Santamaria-Babi, LF, Silvestre, JF. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis. Actas Dermo-Sifiliograficas. 2022; 113(7)DOI:10.1016/j.ad.2021.12.014. PMID:35842249. IF:(Q/D).
01/06/2022
Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials
Chabra, S, Gill, BJ, Gallo, G, Zhu, DT, Pitou, C, Payne, CD, Accioly, A, Puig, L. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. ADVANCES IN THERAPY. 2022; 39(6)DOI:10.1007/s12325-022-02126-0. PMID:35449322. IF:3.800(Q2/4D).
01/06/2022
A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence
Medina-Catalan, D, Riera, P, Pages-Puigdemont, N, Masip, M, Lopez-Ferrer, A, Vilarrasa, E, Puig, L. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. International Journal of Clinical Pharmacy. 2022; 44(3)DOI:10.1007/s11096-022-01400-z. PMID:35380392. IF:2.400(Q3/8D).
01/06/2022
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
de Bruin-Weller, MS, Serra-Baldrich, E, Barbarot, S, Grond, S, Schuster, C, Petto, H, Capron, JP, Raibouaa, A, Werfel, T. Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. Dermatology and Therapy. 2022; 12(6)DOI:10.1007/s13555-022-00734-w. PMID:35543919. IF:3.400(Q2/3D).
01/05/2022
Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19
Sanz, C, Nomdedeu, M, Pereira, A, Sauleda, S, Alonso, R, Bes, M, Brillembourg, H, Garcia-Vidal, C, Millan, A, Martinez-Llonch, N, Piron, M, Puerta-Alcalde, P, Puig, L, Rico, V, Soriano, A. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. TRANSFUSION. 2022; 62(5)DOI:10.1111/trf.16863. PMID:35338710. IF:2.900(Q3/7D).
01/05/2022
The biological basis of disease recurrence in psoriasis: a historical perspective and current models
Puig, L, Costanzo, A, Munoz-Elias, EJ, Jazra, M, Wegner, S, Paul, CF, Conrad, C. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. BRITISH JOURNAL OF DERMATOLOGY. 2022; 186(5)DOI:10.1111/bjd.20963. PMID:34939663. IF:10.300(Q1/1D).
01/05/2022
Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation
Zozaya, N, Villoro, R, Abdalla, F, Alfonso Zamora, S, Balea Filgueiras, J, Carrascosa Carrillo, JM, Delgado Sanchez, O, Dolz Sinisterra, F, Garcia-Ruiz, A, Herranz Pinto, P, Manfredi, A, Martinez Olmos, J, Morales De los Rios Luna, P, Puig Sanz, L, Ros, S, Hildago-Vega, A. Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation. ACTA DERMATO-VENEREOLOGICA. 2022; 102DOI:10.2340/actadv.v102.583. PMID:35312022. IF:3.600(Q1/3D).